Cover Image
市場調查報告書

Lead Pharma Holding B.V. 的產品平台分析

Lead Pharma Holding B.V. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 327906
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Lead Pharma Holding B.V. 的產品平台分析 Lead Pharma Holding B.V. - Product Pipeline Review - 2015
出版日期: 2015年02月28日 內容資訊: 英文 20 Pages
簡介

Lead Pharma Holding B.V. 是總公司在荷蘭的生物製藥企業。進行對慢性心臟衰竭、癌症等的創新治療藥的藥物研發、開發、商品化。著重分子的鑑定和從驗證開始的藥物研發階段的開發平台。

本報告提供Lead Pharma Holding B.V. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Lead Pharma Holding B.V. 的基本資料

  • Lead Pharma Holding B.V. 概要
  • 主要資訊
  • 企業資料

Lead Pharma Holding B.V. :R&D概要

  • 主要的治療範圍

Lead Pharma Holding B.V. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Lead Pharma Holding B.V. :開發中產品概況

  • 初期階段的開發中產品
    • 藥物研發階段的產品/聯合治療模式

Lead Pharma Holding B.V. :藥物簡介

  • Small Molecule for Cancer
  • Small Molecule for Heart Failure-1
  • Small Molecule for Heart Failure-2
  • Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases

Lead Pharma Holding B.V. :開發平台分析

  • 各標靶
  • 各分子類型
  • 各作用機制

Lead Pharma Holding B.V. :最近的開發平台資訊

Lead Pharma Holding B.V. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

目錄
Product Code: GMDHC06820CDB

Summary

Global Markets Direct's, 'Lead Pharma Holding B.V. - Product Pipeline Review - 2015', provides an overview of the Lead Pharma Holding B.V.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lead Pharma Holding B.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Lead Pharma Holding B.V. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Lead Pharma Holding B.V.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Lead Pharma Holding B.V.'s pipeline products

Reasons to buy

  • Evaluate Lead Pharma Holding B.V.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Lead Pharma Holding B.V. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Lead Pharma Holding B.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Lead Pharma Holding B.V. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lead Pharma Holding B.V.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Lead Pharma Holding B.V. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lead Pharma Holding B.V. Snapshot
    • Lead Pharma Holding B.V. Overview
    • Key Information
    • Key Facts
  • Lead Pharma Holding B.V. - Research and Development Overview
    • Key Therapeutic Areas
  • Lead Pharma Holding B.V. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Lead Pharma Holding B.V. - Pipeline Products Glance
    • Lead Pharma Holding B.V. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Lead Pharma Holding B.V. - Drug Profiles
    • Small Molecule for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Heart Failure-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Heart Failure-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lead Pharma Holding B.V. - Pipeline Analysis
    • Lead Pharma Holding B.V. - Pipeline Products by Target
    • Lead Pharma Holding B.V. - Pipeline Products by Molecule Type
    • Lead Pharma Holding B.V. - Pipeline Products by Mechanism of Action
  • Lead Pharma Holding B.V. - Recent Pipeline Updates
  • Lead Pharma Holding B.V. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lead Pharma Holding B.V., Key Information
  • Lead Pharma Holding B.V., Key Facts
  • Lead Pharma Holding B.V. - Pipeline by Indication, 2015
  • Lead Pharma Holding B.V. - Pipeline by Stage of Development, 2015
  • Lead Pharma Holding B.V. - Monotherapy Products in Pipeline, 2015
  • Lead Pharma Holding B.V. - Discovery, 2015
  • Lead Pharma Holding B.V. - Pipeline by Target, 2015
  • Lead Pharma Holding B.V. - Pipeline by Molecule Type, 2015
  • Lead Pharma Holding B.V. - Pipeline Products by Mechanism of Action, 2015
  • Lead Pharma Holding B.V. - Recent Pipeline Updates, 2015
  • Lead Pharma Holding B.V., Other Locations
  • Lead Pharma Holding B.V., Subsidiaries

List of Figures

  • Lead Pharma Holding B.V. - Pipeline by Top 10 Indication, 2015
Back to Top